ImmunoTherapeutics Inc. announced that it has started PhaseII clinical trials of ImmTher, its immunomodulator for treatingcolorectal cancer, at the University of Texas M.D. AndersonCancer Center in Houston.
ImmTher is a macrophage activator, explained Gerald Vosika,the president and scientific director of the Moorhead, Minn.,company. It's an "essentially synthetic material" based oncomponents of the cell wall of BCG, an attenuated strain of thetubercular bacterium, Vosika said.
Initial Phase I studies of ImmTher showed significantregression of metastatic colorectal cancer in some patients. AndImmunoTherapeutics has already taken its drug through onePhase II trial in 18 patients whose cancer had spread to theliver, even after prior chemotherapy. In that trial, ImmTherarrested the disease in 12 of the patients for periods of sixweeks to six months. The new Phase II will be in previouslyuntreated patients.
(c) 1997 American Health Consultants. All rights reserved.